We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease ... Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). Show more
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet...
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0591 | -7.98540737738 | 0.7401 | 0.7689 | 0.6774 | 402958 | 0.72635925 | CS |
4 | -0.019 | -2.71428571429 | 0.7 | 0.87 | 0.6774 | 492824 | 0.77289912 | CS |
12 | -4.639 | -87.1992481203 | 5.32 | 5.95 | 0.6711 | 1424087 | 1.09606222 | CS |
26 | -0.689 | -50.2919708029 | 1.37 | 5.95 | 0.6711 | 828497 | 1.57873269 | CS |
52 | -1.729 | -71.7427385892 | 2.41 | 5.95 | 0.6711 | 464616 | 1.62026225 | CS |
156 | -13.159 | -95.0794797688 | 13.84 | 15.08 | 0.6711 | 658454 | 3.28514957 | CS |
260 | -16.319 | -95.9941176471 | 17 | 35.6 | 0.6711 | 557550 | 3.68782968 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions